Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Suzanne G. Courter"'
Autor:
Suzanne G. Courter, Martin Lee
Publikováno v:
Drug Information Journal. 28:39-43
The utility of quality of life assessments as a means of determining the cost effectiveness of a new therapeutic intervention cannot be overstated. Nonetheless, under certain circumstances such an approach may be misleading given the conditions under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbddd34a075334b1929477007f3f90c1
https://doi.org/10.1177/009286159402800106
https://doi.org/10.1177/009286159402800106
Autor:
Bonita J. Rup, Craig M. Kessler, K. John Pasi, Suzanne G. Courter, David A. Roth, Karen L. Tubridy
Publikováno v:
Blood. 98(13)
Human plasma–derived factor IX (pdFIX) concentrates are routinely used to treat patients with hemophilia B, an X-linked bleeding disorder that affects 1 in 30 000 males, but concerns remain regarding transmission of blood-borne pathogens. Therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d3a433f8576356b9638436776506eb
https://pubmed.ncbi.nlm.nih.gov/12433699
https://pubmed.ncbi.nlm.nih.gov/12433699
Autor:
Recombinate, Dorothea Scandella, Richard Prescott, Suzanne G. Courter, Matthew Felch, Pamela C. Esmon, Craig M. Kessler, Edward D. Gomperts, Deborah Hurst, Kogenate Study groups
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9781461380016
Alloantibodies that inactivate factor VIII (F.VIII) develop in up to 24% of hemophilia A patients given therapeutic infusions of F.VIII. The probability of inhibitor formation is greatest in individuals with severe hemophilia (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9d8633ea3b09657c8af5e713b576d2b
https://doi.org/10.1007/978-1-4613-0331-2_4
https://doi.org/10.1007/978-1-4613-0331-2_4
Publikováno v:
Journal of clinical immunology. 13(4)
The use of intravenous immunoglobulin is standard practice for antibody replacement in the humoral immunodeficiency diseases. Most infusions proceed uneventfully, but a proportion of infusions (5-8%) produces some degree of an infusion reaction. Whil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e272650221b2e77fd16896d88f6cd2
https://pubmed.ncbi.nlm.nih.gov/8227286
https://pubmed.ncbi.nlm.nih.gov/8227286
Autor:
Kanti R. Rai, Dierdre Tait, Kenneth A. Foon, Helen Chapel, Robert Peter Gale, C. Bunch, Suzanne G Courter
Publikováno v:
New England Journal of Medicine. 319:902-907
In a double-blind study, we randomly assigned 84 patients with chronic lymphocytic leukemia who were judged to be at increased risk of bacterial infection to receive intravenous immunoglobulin G (400 mg per kilogram of body weight) or a placebo every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::083c60bc08f8d702206d475f42e6b900
https://doi.org/10.1056/nejm198810063191403
https://doi.org/10.1056/nejm198810063191403
Autor:
Robert Peter, Gale, Helen M, Chapel, Christopher, Bunch, Kanti R, Rai, Kenneth, Foon, Suzanne G, Courter, Dierdre, Tait
Publikováno v:
The New England journal of medicine. 319(14)
In a double-blind study, we randomly assigned 84 patients with chronic lymphocytic leukemia who were judged to be at increased risk of bacterial infection to receive intravenous immunoglobulin G (400 mg per kilogram of body weight) or a placebo every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::879a5d7c25deef85cb1cfe67ac0b78d0
https://pubmed.ncbi.nlm.nih.gov/2901668
https://pubmed.ncbi.nlm.nih.gov/2901668